Clinical Trials in Switzerland – are we ready for the future?

Clinical Trials in Switzerland – are we ready for the future?

Friday, September 11, 2026

On Wednesday afternoon I attended a mini-conference on “Clinical Trials in Switzerland – are we ready for the future?” at the University of Basel.

The conference included contributions from Parliament, the regulator, research, industry, patient representatives and a global CRO.  Although the speakers approached the issue from different positions, several themes recurred.

Switzerland still runs a considerable number of commercial trials for its size. In 2025, there were 162 Category B and C medicinal-product trials, mainly Phase 3 (89) and Phase 2 (49). At the same time, trial activity has not grown in line with global developments, and early-stage and academic research appear to have weakened compared with 2016.

The stakes are wider than research activity alone. Trials can give patients earlier access to new treatments, help Swiss investigators develop international visibility, and strengthen the evidence base and relationships relevant to later market-access, HTA and pricing-and-reimbursement discussions.

The practical determinants of competitiveness were clear:

  • Faster time to first patient
  • Rapid recruitment
  • Better use of connected health data to identify potentially eligible participants

Swissmedic’s clinical trial fast-track pilot introduced in July 2025 is therefore a notable step. The reported 33% acceleration in review for eligible submissions suggests that meaningful process improvements are possible.

However, speakers also highlighted unresolved issues: variable ethics-review timelines, limited trial visibility for patients and clinicians, fragmented health data, and pressure on funding for academic research.

Three legislative changes are currently being discussed addressing Switzerland’s attractiveness as a clinical trial location and life sciences hub overall.

My conclusion is not that Switzerland lacks the assets to compete. Rather, the policy challenge is to connect those assets more effectively.

#ClinicalResearch #ClinicalTrials #SwissHealthPolicy #Swissmedic #HealthData #LifeSciences #EliboHealth

If you want more details, here’s the link to the Whitepaper published following the event: English version: BeOne HCP | CH-EN

German version: BeOne HCP | CH-EN

Search